Back

Mortality and characteristics among four DOACs and warfarin.

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Latest science in atrial fibrillation Anticoagulants ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Masanari Kuwabara

Jichi Medical University, Shimotsuke (Japan)

3 More presentations in this session

Presentation thumbnail
The LOOP Study - Stroke severity and etiology in patients screened for atrial fibrillation versus usual care
Doctor S. Diederichsen (Copenhagen, DK)
Slides Video
Presentation thumbnail
Early Rhythm-Control Therapy and High Comorbidity Burden.
Doctor J. Dickow (Hamburg, DE)
Slides Video
Presentation thumbnail
Predictors and mediators of improved outcomes on early rhythm control an analysis of the EAST AFNET - 4 data set.
Professor L. Eckardt (Muenster, DE)
Slides Video

Access the full session

Session thumbnail
Latest science in atrial fibrillation
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Association between warfarin and direct oral anticoagulants users and risk of mortality: cohort studies in England and Hong Kong
thumbnail
Congress Presentation
Incidence, management and outcomes of patients with incident atrial fibrillation in the contemporary direct oral anti coagulants era. A national study
thumbnail
Congress Presentation
Rivaroxaban or warfarin in atrial fibrillation and coronary stent implantation in real-world patients involving chronic kidney disease (REWRAPS): 5-year follow-up study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources